Aggressive behavior and clinical course of parathyroid carcinoma: a case report and review of the literature

Keywords

Hyperparathyroidism
carcinoma
hypercalcemia
parathyroid neoplasia
Osteoporosis
Diabetes Mellitus

How to Cite

Plata Upegui , C., Hernandez Caicedo, A. J., & Plata Upegui, L. J. (2022). Aggressive behavior and clinical course of parathyroid carcinoma: a case report and review of the literature. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 9(2). https://doi.org/10.53853/encr.9.2.690

Abstract

Context: Primary hyperparathyroidism, is the third most frequent endocrine disorder. It is rarely caused by parathyroid carcinoma, an infrequent entity, difficult to diagnose and with a high recurrence and mortality rate.

Objective: To present the clinical course and approach to parathyroid carcinoma, emphasizing the pre-surgical clinical suspicion criteria, which are determinant in the initial surgical planning.

Methodology: The case of a young woman with severe hypercalcemia due to parathyroid carcinoma was presented. The behavior of the disease, complications and interventions received were documented. Correlation was made with the literature review, in terms of clinical manifestations, diagnosis, therapeutic options and importance of follow-up.

Results. The feedback of the actions taken with the patient was performed. The pre-surgical suspicion criteria were highlighted, in contrast with the available imaging studies, highlighting their advantages and disadvantages. The repercussions on hypercalcemia, which pharmacological and surgical interventions have, were identified.

Conclusions: Parathyroid carcinoma is a neoplasm of difficult diagnosis and high impact on patients' lives. Pre-surgical clinical suspicion is determinant for the initial surgical approach, since the complete elimination of the disease is the therapeutic objective. Survival is related to the control of hypercalcemia and long-term clinical follow-up, due to several therapeutic interventions are available to improve life expectancy.

https://doi.org/10.53853/encr.9.2.690

References

Fraser WD. Hyperparathyroidism. Lancet. 2009 jul;374(9684):145-58.

Disponible en: doi: 10.1016/S0140-6736(09)60507-9. PMID: 19595349.

Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. The Lancet. 2018 Sept;391 (10116) :168-178. Disponible en: https://doi.org/10.1016/S0140-6736(17)31430-7

Takenobu M, Moritani S, Kawamoto K, Yoshioka K, Kitano H. Parathyroid carcinoma coexisting with multiple parathyroid adenomas: a case report. Endocr J. 2020 Sep 28;67(9):963-967. doi: 10.1507/endocrj.EJ20-0139.

Dudney WC, Bodenner D, Stack JrB. Parathyroid Carcinom. Otolaryngologic Clinics of North America.2010; 43(2):441-453. Disponible en: https://doi.org/10.1016/j.otc.2010.01.011

Talat N, Schultze KM.Clinical presentation, staging and long-term evolution of parathyroid cancer. Ann Surg Oncol.2010 mzo; 17(8). 2156-2174 . Disponible en: https://doi.org/10.1245/s10434-010-1003-6

Betea D, Potorac L, Beckers A. Parathyroid carcinoma: Challenges in diagnosis and treatment. Annales d'Endocrinologie.2015; 76(2), 169–177. Disponible en: Doi:10.1016/j.ando.2015.03.003

Quinn CE, Healy J, Lebastchi AH, et al. Modern experience with aggressive parathyroid tumors in a high-volume New England referral center. J Am Coll Surg 2015; 220:1054. Disponible en: DOI:10.1016/j.jamcollsurg.2014.10.007

Hsu P, Liu CY, Chen MH. Refractory hypercalcemia due to hyperparathyroidism in a patient with metastatic parathyroid carcinoma. Journal of Cancer Research and Practice.2018 en; 5(2): 84-87. Disponible en: https://doi.org/10.1016/j.jcrpr.2018.01.002.

Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab. 1996 Jun;81(6):2036-40. Disponible en: https://doi: 10.1210/jcem.81.6.8964825. PMID: 8964825

. Walker MD, Rubin M, Silverberg SJ. Nontraditional Manifestations of Primary Hyperparathyroidism. Journal of Clinical Densitometry. 2013; 16(1): 40–47. Disponible en: https://doi.org/10.1016/j.jocd.2012.11.008

Quaglino F, Manfrino L, Cestino L, et al. Parathyroid Carcinoma: An Up-to-Date Retrospective Multicentric Analysis. Int J Endocrinol. 2020;2020:7048185. Published 2020 Mar 6. Disponible en: Doi:10.1155/2020/7048185

Mohebati A, Shaha A,Shah J. Parathyroid Carcinoma. Hematology/Oncology Clinics of North America.2012;26(6), 1221–1238. Disponible en: doi:10.1016/j.hoc.2012.08.009

Sadler C, Gow KW, Beierle EA, Doski JJ, Langer M, Nuchtern JG, Vasudevan SA, Goldfarb M. Parathyroid carcinoma in more than 1,000 patients: A population-level analysis. Surgery (United States). 2014 dic; 156(6): 1622-1630 Disponible en: https://doi.org/10.1016/j.surg.2014.08.069

Schulte KM, Talat N. Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol.2012; 8(10):612-622 Disponible en: https://doi:10.1038/nrendo.2012.102

Schulte KM, Gill AJ, Barczynski M, Karakas E, Miyauchi A, Knoefel WT, Lombardi CP, Talat N, Diaz-Cano S, Grant CS. Classification of parathyroid cancer. Ann Surg Oncol.2012;19(8):2620-2628 Disponible en: doi:10.1245/s10434-012-2306-6

Yip L, Seethala RR, Nikiforova MN, Nikiforov YE, Ogilvie JB, Carty SE, Yim JH. Loss of heterozygosity of selected tumor suppressor genes in parathyroid carcinoma. Surgery.2008;144(6):949–955. Disponible en: doi: 10.1016/j.surg.2008.08.030

Givi B, Shah JP. Parathyroid carcinoma. Clinical oncology (Royal College of Radiologists.2012 abr;22(6): 498-507. Disponible en: DOI:10.1016/j.clon.2010.04.007

Basceken S, Genc V, Ersoz S, Sevim Y, Celik S, Bayram I.Is local resection sufficient for parathyroid carcinoma?. Clinics.2015; 70(4): 247–249. Disponible en: doi:10.6061/clinics/2015(04)05

Rodrigo JP, Hernandez JC, Randolph GW, Zafereo ME, Hartl DM, Silver CE.; Suarez C, Owen RP, Bradford CR.; MÃakitie AA, Shaha AR, Bishop JA, Rinaldo, A, Ferlito A.Parathyroid cancer: An update. Cancer Treatment Reviews.2020;86:102012. Disponible en: doi:10.1016/j.ctrv.2020.102012

Campenni A, Ruggeri RM, Sindoni A, Giovinazzo S, Calbo E, Ieni A, et al. Parathyroid carcinoma presenting as normocalcemic hyperparathyroidism. J Bone Miner Metab 2012;3:367–72. Disponible en: https://doi.org/10.1007/s00774-011-0344-y

Barberán M, Campusano C, Salman P, Trejo P, Silva A, Rivera S, Florenzano P, Velasco S, Illanes F, Trincado P, Canessa J, Solar A, Moreno M, Eugenin D, Jiménez B, Arroyo P. An update on parathyroid carcinoma. Revista médica de Chile.2021; 149(3), 399-408. Disponible en: https://dx.doi.org/10.4067/s0034-98872021000300399

Jo IH, Paik CN. Acute Pancreatitis with Hypercalcemia as Initial Manifestation of Multiple Myeloma. Korean J Gastroenterol. 2020 Apr 25;75(4):220-224. Disponible en: Doi: 10.4166/kjg.2020.75.4.220. PMID: 32326690.

Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol.2012; 13(1):11-23. Disponible en: doi:10.1007/s11864-011-0171-3

Haring A, Avatinka W, Fernandez RG, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metabol.2001; 96(12), 3679–3686. Disponible en: doi:10.1210/jc.2011-1571

NICE guideline. Hyperparathyroidism (primary): diagnosis, assessment, and initial management. United Kingdom.2019. Disponible en: https://www.nice.org.uk/guidance/ng132

Hetrakul N, Civelek AC, Stagg CA, Udelsman R. In vitro accumulation of technetium-99m-sestamibi in human parathyroid mitochondria. Surgery.2001 dic; 130(6):1011–1018. Disponible en: https://doi.org/10.1067/msy.2001.118371

Kitapçi MT, Tastekin G, Turgut M, Caner B, Kars A, Barista I, Bekdik C. Preoperative localization of parathyroid carcinoma using Tc-99m MIBI. Clin Nucl Med.1993 dic;18(3):217-9. Disponible en: doi: 10.1097/00003072-199303000-00007. PMID: 8462212

Chen CC, Holder LE, Scovill WA, Tehan AM, Gann DS. Comparison of parathyroid imaging with technetium-99m-pertechnetate/sestamibi subtraction, double-phase technetium-99m-sestamibi and technetium-99m-sestamibi SPECT. J Nucl Med.1997;38 (6):834-9. Disponible en: PMID: 9189125

Johnson NA, Yip L, Tublin ME. Cystic Parathyroid Adenoma: Sonographic Features and Correlation With 99mTc-sestamibi SPECT findings. American Journal of Roentgenology.2010;195(6), 1385–1390. Disponible en: doi:10.2214/AJR.10.4472

Agarwal G, Dhingra S, Mishra SK, Krishnani N. Implantation of parathyroid carcinoma along fine needle aspiration track. Langenbecks Arch Surg 2006;391:623–6. Disponible en: https://doi.org/10.1007/s00423-006-0095-8.

Harari A, Waring A, Fernandez-Ranvier G, Hwang J, Suh I, Mitmaker E, et al.Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab.2011;96:3679–86. Disponible en: https://doi.org/10.1210/jc.2011-1571.

Sidhu PS, Talat N, Patel P, et al.Ultrasound features of malignancy in the preoperative diagnosis of parathyroid cancer: a retrospective analysis of parathyroid tumours larger than 15 mm. Eur Radiol.2011; 21(9):1865–1873. Disponible en: https://doi.org/10.1007/s00330-011-2141-3

Kebebew E, Arici C, Duh QY, Clark OH. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg.2001; 136(8):878-85. Disponible en: doi: 10.1001/archsurg.136.8.878.

Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G. PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol.2009; 70(3): 382-392. Disponible en: DOI: 10.1016/j.ejrad.2009.03.051

Jones RL, Cunningham D, Cook G, Ell PJ.Tumour vaccine associated lymphadenopathy and false positive positron emission tomography scan changes. Br J Radiol.2004;77(913): 74-75. Disponible en: doi:10.1259/bjr/19323466

Evangelista L, Sorgato N, Torresan F, et al. FDG-PET/CT and parathyroid carcinoma: Review of literature and illustrative case series. World Journal of Clinical Oncology.2011; 2(10):348-354. Disponible en: DOI: 10.5306/wjco.v2.i10.348.

Arslan N, Rydzewski B. Detection of a recurrent parathyroid carcinoma with FDG positron emission tomography. Clin Nucl Med.2002;27(3):221-2. Disponible en: doi: 10.1097/00003072-200203000-00022. PMID: 11852320.

Gardner CJ, Wieshmann H, Gosney J, Carr HM, Macfarlane IA, Cuthbertson DJ. Localization of metastatic parathyroid carcinoma by 18F FDG PET scanning. J Clin Endocrinol Metab.2010;95(11):4844-5. Disponible en: DOI: 10.1210/jc.2010-1479. PMID: 21051579

Christakis I, Vu T, Chuang HH, Fellman B, Figueroa AMS, Williams MD, et al. The diagnostic accuracy of neck ultrasound, 4D-Computed tomography and sestamibi imaging in parathyroid carcinoma. Eur J Radiol 2017; 95: 82-8. Disponible en: DOI: 10.1016/j.ejrad.2017.07.026

Huber G, Hüllner M, Schmid C, Brunner A, Sah B, Vetter D, et al. Benefit of 18 F- fluorocholine PET imaging in parathyroid surgery. Eur Radiol. 2018; 28:2700–7. Disponible en: https://doi.org/10.1007/s00330-017-5190-4.

Deandreis D, Terroir M, Al Ghuzlan A, Berdelou A, Lacroix L, Bidault F, et al. 18Fluorocholine PET/CT in parathyroid carcinoma: a new tool for disease staging?. Eur J Nucl Med Mol Imag. 2015;42:1941–2. Disponible en: https://doi.org/10.1007/s00259-015-3130-6.

Boccalatte LA, Gómez NL, Musumeci M, Galich AM, Collaud C, Figari MF.

PET/TC 4D 18F-colina en el hiperparatiroidismo: correlación entre datos bioquímicos y parámetros del estudio. Revista Española de Medicina Nuclear e Imagen Molecular.2020;39(5):273-278. Disponible en: https://doi.org/10.1016/j.remn.2020.03.017.

.

Quak E, Blanchard D, Houdu B, Le Roux Y, Ciapuccini R, Lireux B, et al. F18-choline PET/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT/CT are negative or inconclusive: the APACH1 study. Eur J Nucl Med Mol Imaging 2018; 45(4): 658-66. Disponible en: DOI: 10.1007/s00259-017-3911-1

Sillero A, Atienza MA.Manejo diagnóstico-terapéutico del carcinoma de paratiroides. Anales de Medicina Interna.2002;19(12), 48-52.

Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-71992002001200010&lng=es&tlng=es.

Hsu P, Liu CY, Chen MH. Refractory hypercalcemia due to hyperparathyroidism in a patient with metastatic parathyroid carcinoma, Journal of Cancer Research and Practice. 2018; 5 (2): 84-87. Disponible en: doi: 10.1016/j.jcrpr.2018.01.002.

Brandi ML. Parathyroid Disorders. Focusing on Unmet Needs. Front Horm Res. Basel, Karger.2019;51: 63–76. Disponible en: DOI: 10.1159/000491039.

Rathi MS, Ajjan R, Orme SM. A case of parathyroid carcinoma with severe hungry bone syndrome and review of literature. Exp Clin Endocrinol Diabetes.2008;116(8):487-90. Disponible en: doi: 10.1055/s-2007-992155

Shane E. Clinical review 122: Parathyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism.2001;86(2): 485-493. Disponible en: https://doi.org/10.1210/jcem.86.2.7207

Duan K, Ozgur M. Parathyroid carcinoma: diagnosis and clinical implications. Turkish Journal of Pathology.2015;31 Suppl 1:80-97. Disponible en: Doi:10.5146/tjpath.2015.01316

U.S. Food and Drug Administration (FDA). FDA Drug Safety Communication: New contraindication and updated warning on kidney impairment for Reclast (zoledronic acid) [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2011. Disponible en: http://www.fda.gov/Drugs/DrugSafety/ucm270199.htm

Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia BMJ. 2015;350:h2723. Disponible en: doi:10.1136/bmj.h2723

Long Kl, Sippel RS. Current and future treatments for parathyroid carcinoma. International Journal of Endocrine Oncology2018; ije-2017-0011. Disponible en: doi:10.2217/ije-2017-0011

Silverberg SJ, Rubin MR, Faiman C et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism.2007;92: 3803-3808 Disponible en: https://doi.org/10.1210/jc.2007-0585

Vaira V, Elli F, Forno I, Guarnieri, V, Verdelli C, Ferrero S, Scillitani A, Vicentini L, Cetani F, Mantovani G, Spada A, Bosari S, Corbetta S.The microRNA cluster C19MC is deregulated in parathyroid tumours. Journal of Molecular Endocrinology.2012;49(2):115–124. Disponible en: doi:10.1530/jme-11-0189

Hsu KT, Sippel RS, Chen H, Schneider DF.Is central lymph node dissection necessary for parathyroid carcinoma? .Surgery.2014;156(6): 1336-1341. Disponible en: Doi:10.1016/j.surg.2014.08.005

Gao WC, Ruan CP, Zhang JC, et al. Nonfunctional parathyroid carcinoma. Journal of Cancer Research and Clinical Oncology. 2010;136(7):969–74. Disponible es :Doi: 10.1007/s00432-009-0740-z.

Wilkins BJ, Lewis J. S. Nonfunctional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. Head and Neck Pathology . 2009;3(2):140–149. Disponible en: Doi: 10.1007/s12105-009-0115-4

Ferraro V, Sgaramella LI, Di Meo G, Prete FP, Logoluso F, Minerva F, et al. Current concepts in parathyroid carcinoma: a single Centre experience. BMC Endocr Disord. 2019;19 Suppl 1:46. Disponible en: 10.1186/s12902-019-0368-1

De Pasquale L, Bulfamante AM, Felisati G, Castellani L, Ghilardi G, Saibene AM. Management and Outcome of Parathyroid Carcinoma-Induced Primary Hyperparathyroidism: A Single-Centre Experience. Int J Endocrinol. 2021;2021:5397941. Disponible en: doi:10.1155/2021/5397941

Sandelin K, Tullgren O, Farnebo LO. Clinical course of metastatic parathyroid cancer. World J. Surg. 18, 594–598 (1994). Disponible en :https://doi.org/10.1007/BF00353773.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2022 Revista Colombiana de Endocrinología, Diabetes & Metabolismo

Dimensions


PlumX


Downloads

Download data is not yet available.